Oncology has experienced progress at breakneck speed, with recent discoveries leading to the development of new drugs that have revolutionised cancer treatment. The clinical use of genomic data and the large production of data has truly brought upon us an era of precision medicine and has levered progress in fundamental, translational and clinical research. The conclusion is evident: it is no longer possible to practice medicine without taking multidisciplinary and translational medicine into account.

The Congress will cover the most recent scientific advances, demonstrating how fundamental and translational science have become essential to the success of clinical oncologists. The aim is to promote interaction between researchers and clinical oncologists so the decisions are even more accurate. Given the theme relevance for Clinical Oncology, the event will also include a pre-course entitled ‘Molecular Biology for Clinical Oncologists: What do we have to know?’, so that clinical oncologists and health professional comprehend and interact with the tools of basic science even more safely.

Organizing committee
SBOC-AACR Joint Congress:
A Translational Approach to Clinical Oncology

  Dr. Clarissa  

  Dr. margaret  

Chief Executive Officer,


  Dr. Sérgio  

  Dr. paulo  

  Dr. carlos  

  Dr. manuel  

days until the congress!

view more

Oncologista Clínico do Hospital Israelita Albert Einstein Head da Área de Medicina Personalizada do Hospital Israelita Albert Einstein Co-Founder da Delfi Diagnostics, Inc. (Baltimore, EUA) PhD em Genômica de Câncer pela Johns Hopkins University (Baltimore, EUA) Residência em Oncologia Clínica pelo ICESP / HCFMUSP
Clinical Oncologist Director - Grupo Dom ONCologia President - Brazilian Group of Head and NEck Cancer
Bióloga formada pela Universidade de São Paulo com doutorado pela mesma instituição e pós doutorado no Instituto Ludwig de Pesquisa sobre o Câncer. Atualmente é Pesquisadora e Coordenadora do Centro de Oncologia Molecular do Hospital Sírio Libanês. Atua na área de genética e genômica do câncer.
Professor da Escola de Medicina e do Programa de Pós-graduação da PUCRS. Coordenador Médico do Centro de Oncologia Oncoclínicas-Hospital São Lucas da PUCRS. Pesquisador Visitante da Dana-Farber Cancer Institute/Harvard Medical School. Membro do "steering committee" do LACOG-GU. Membro efetivo do comitê de tumores urológicos da SBOC.
Pós-doutorado MGH/Harvard University Professora e pesquisadora UFMG Presidente do Grupo Brasileiro de Tumores Ginecológicos, EVA. Diretora Técnica DOM Oncologia.
Anthony G. Letai, MD, PhD, is a Physician at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. His research focuses on the mechanisms by which cancer cells evade death, and on the application of that knowledge to the selective killing of cancer cells. Key to this research is a novel assay – BH3 profiling – which he has employed to lead efforts to translate BCL-2, BCL-XL and MCL-1 inhibitors into the clinic.
Chefe do Serviço de Oncologia Clinica do Centro de Oncologia do Hospital Sírio Libanês Ex Presidente da SBOC
Títulos e filiações Membro da Sociedade Brasileira de Oncologia Clínica (SBOC) Título de especialista em Cancerologia Clínica pela Sociedade Brasileira de Cancerologia Membro da Sociedade Americana de Oncologia Clínica (ASCO) Áreas de Interesse Tumores Gênito-urinários Tumores de Cabeça e Pescoço Tumores da mama Formação profissional Graduação na Escola Bahiana de Medicina e Saúde Pública (1993) Residência em Clínica Médica no Hospital das Clínicas da Faculdade Medicina da USP-SP (1994-1995) Residência em Hematologia e Hemoterapia no Hospital das Clínicas da Faculdade Medicina da USP-SP (1995-1997) Fellowship em Oncologia Clínica Na Universidade Yale (EUA, 1998-2000) Doutor em Medicina e Saúde Humana pela Fundação para o Desenvolvimento das Ciências / Fiocruz (2006)
DR. BERNARDO GARICOCHEA CRM (SP): 47.162 Médico do Centro de Oncologia do Hospital Sírio-Libanês – Unidade Bela Vista Coordenador de Ensino e Pesquisa do Centro de Oncologia do Hospital Sírio-Libanês Formação • Graduação médica na Pontifícia Universidade Católica do Rio Grande do Sul; • Mestrado e doutorado pela universidade de São Paulo • Pós-doutorado em Biologia Molecular pelo Royal Postgraduate Medical School of London; • Pós-doutorado em Genética Oncológica pelo Memorial Sloan Kettering Cancer Center - Nova York.
Carlos Gil Ferreira, MD, PhD. Oncologista clínico, doutor em oncologia experimental pela Vrije Universiteit Medical Center, Amsterdã, Holanda. Presidente e diretor científico do Instituto Oncoclínicas.
Carlos H. Barrios M.D. is Director of the Oncology Research Center at Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS). He is Director of LACOG, Latin American Cooperative Oncology Group, Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine, Florida and physician member of the Oncoclinicas Group.. Dr. Barrios received his medical degree from Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), in Porto Alegre, RS, Brazil. He is Board certified in Internal Medicine being trained at the Hospital de Clínicas, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil and Jackson Memorial Hospital, University of Miami, Miami, Florida. Is also Board Certified in Hematology and Oncology training at Barnes and Jewish Hospitals, Washington University, Saint Louis, Missouri. Dr. Barrios is member of the Executive Board of the Breast International Group (BIG) and is very interested in clinical research participating in over 250 industry sponsored and academic clinical trials over the last 20 years. He has many abstract presentations in national and international congresses and has contributed significantly in the literature with peer reviewed publications. He has a strong interest in the development of international research collaborations and implementation of cooperative research infrastructures in Latin America. He is cofounder and current director of LACOG (Latin American Cooperative Oncology Group), which congregates more than 100 investigators in more than 70 institutions from 14 different countries in Latin America.
Médica oncologista do NOB/Oncoclínicas, chair do Conselho Internacional da Sociedade Americana de Oncologia Clínica (ASCO), presidente da Sociedade Brasileira de Oncologia Clínica (SBOC).
Coordenador científico da Oncologia D‘Or e coordenador do programa de residência em oncologia clinica. Linha de pesquisa com foco em novas terapias, combinações com radioterapia, imunoterapia e pesquisa translacional. Membro efetivo da Academia de Medicina do Rio de Janeiro (AMRJ)
- Medical Oncologista at Hospital Moinhos de Vento, Porto Alegre, Brazil; - MSc and PhD in Medical Sciences at Federal University of Rio Grande do Sul, Porto Alegre, Brazil; - Post-doctorade at Paterson Institute for Cancer Research, Manchester, UK (supported by CAPES from Brazil); - Fellowship in Breast Cancer at Jules Bordet Institute, Brussels, Belgium; - Head of the Brazilian Breast Cancer Study Group (GBECAM).
Doutor em oncologia pelo AC Camargo Cancer Center, Conselheiro Científico do Grupo Brasileiro de Tumores Gastrointestinais, chefe do Serviço de Oncologia Clínica do Hospital Walter Cantídio (UFC-CE)
Dr. Dung Le is an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University in Baltimore, Maryland. She is a member of the Gastrointestinal Malignancies Division of Medical Oncology. Dr. Le received her undergraduate degree at Yale University and underwent internal medicine and oncology fellowship training at Johns Hopkins University. Her research interests include novel approaches to patients with gastrointestinal malignancies. Her main research focuses are on combination immunotherapy strategies or the use of predictive biomarkers to improve responses to immunotherapy. She has helped lead the development of programmed death-1 (PD-1) blockade in tumors with mismatch repair deficiency across disease types which led to the first biomarker selection tissue agnostic FDA approval. She is also testing multiple combinations with immune checkpoint blockade in the hopes of improving responses to immunotherapy in gastrointestinal malignancies.
Dr. Sotomayor received his MD degree from Federico Villarreal National University School of Medicine in Lima, Peru. He completed a residency training in Internal Medicine at Jackson Memorial Hospital/University of Miami School of Medicine in Florida, followed by a fellowship in Medical Oncology at Johns Hopkins University in Baltimore, Maryland. His translational/clinical research for the past twenty years has focused on the field of cancer immunology and immunotherapy with special emphasis in B-cell malignancies. He has published more than 130 manuscripts, including seminal publications in top tier journals such as Nature Medicine, Nature Immunology, Immunity, Cancer Cell, Proceedings of the National Academy of Sciences, Journal of Clinical Investigations, Blood, Cancer Research and Journal of Immunology. He has received multiple grants from the Lymphoma Research Foundation (LRF), the National Cancer Institute and biotech/pharmaceutical companies. Dr. Sotomayor is a member of the Scientific Advisory Board, Lymphoma Research Foundation, member of the Executive Committee of the Mantle Cell Lymphoma Consortium, member of the Science Policy and Government Affairs Committee, American Association for Cancer Research (AACR), Chair, Latin American Regional Advisory Group, International Affairs Committee, AACR, member of the Hematologic Malignancies Task Force at AACR, member Cancer Immunology and Immunotherapy (CIMM) Steering Committee at AACR and a former member, National Cancer Institute, Subcommittee A, Cancer Centers.
Possui graduação em Ciências Biológicas pela Universidade Federal de Minas Gerais (1989), Mestrado em Biologia Celular e Molecular pela Fundação Oswaldo Cruz (1994), Doutorado em Bioquímica e Imunologia pela Universidade Federal de Minas Gerais (1997) e Pós-Doutorado em Genômica do Câncer pelo Ludwig Institute for Cancer Research (1999). Foi pesquisador sênior do Instituto Ludwig de Pesquisas sobre o Câncer (até 2002), vice-diretor do Laboratório de Neurociências (LIM-27) no Instituto de Psiquiatria da Faculdade de Medicina da USP (até 2006) e Professor Visitante na University of Texas, MD Anderson Cancer Center (até Setembro de 2009). Atualmente é cientista adjunto no Centro Internacional de Pesquisas do AC Camargo Cancer Center, onde coordena o Laboratório de Genômica Médica. Tem experiência na área de Biologia Molecular e Genômica.
Obtained his medical degree at UFF (Niterói) and completed residency in Anatomic Pathology at INCa (Rio de Janeiro). Holds a Master Degree in Neuropathology (UFRJ, Rio de Janeiro). Lived for eleven years in Paris, France, where he obtained a PhD on molecular pathology of pediatric brain tumors (Université Paris XI) and worked as a fellow, then as a pathologist/ neuropathologist at Gustave Roussy and Hôpital Ste-Anne. Moved to Germany in 2016 pursuing his activities at the National Reference Center for the Diagnosis of Brain Tumors (Bonn). Since 2020 works as a neuropathologist at Instituto Estadual do Cérebro Paulo Niemeyer and Rede D’Or/IDOR (Rio de Janeiro).
Assistant Professor of Medicine Division of Hematology/Medical Oncology Weill Cornell Medicine/NewYork-Presbyterian
Médico Assistente Doutor do Serviço de Oncologia Clínica do Instituto do Câncer do Estado de São Paulo e Médico Titular do Centro do Oncologia do Hospital Sírio Libanês, São Paulo - SP. Professor Doutor - Disciplina da Oncologia da Faculdade de Medicina da USP
Diretor Geral Unidade Brasília, do Hospital Sírio-Libanês; Advanced Clinical Fellow (MSKCC); Ex Presidente da Sociedade Brasileira de Oncologia Clínica – SBOC (gestão 2015/2017); Residência em Cancerologia no Hospital Sírio-Libanês, São Paulo, Brasil; Residência em Clínica Médica e Hematologia no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP); Graduação em medicina pela Universidade Federal da Paraíba (UFPB).
Oncologia pelo HC de SP Doutor em oncologia pela USP Pós-Doc pela Universidade Federal de Pernambuco Oncologista do Santa Joana Recife (Americas UHG) e do HC de Pernambuco Professor de Oncologia da Universidade Católica de Pernambuco Membro da SBOC e da ASCO
- Medical Oncologist at Hospital Israelita Albert Einstein - MD by the Federal University of São Paulo - Medical Oncology Fellowship at The University of Texas MD Anderson Cancer Center - PhD at Hospital Israelita Albert Einstein
Oncologia pela northwestern university Médico do instituto nacional de çqncer Doutor pelo instituto nacional de câncer
Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus‘s lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as an Associate Professor in the Departments of Pathology and Internal Medicine (in the Section of Medical Oncology). Her laboratory is focused on studying the biology of lung cancer and on uncovering mechanisms of resistance to targeted therapies and immunotherapies in this disease. At the Yale Cancer Center, Dr. Politi is a co-leader of the Cancer Signaling Networks Research Program.
Assistant Professor of Medical Oncology in the Sidney Kimmel Comprehensive Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University, Baltimore, Maryland
Mestre e Doutor em Medicina Ex-Fellow da American Society of Clinical Oncology Ex-Postdoctoral Researcher da Ohio State University Médico Oncologista e Pesquisador do INCA/MS Diretor Científico do Instituto COI Assessor Médico do Laboratório Progenética/Pardini
Manuel Hidalgo, M.D., Ph.D. is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital. He is also the Hugh E. Luckey Distinguished Professor of Medicine at Weill Cornell Medical Collge. Dr. Hidalgo received his MD degree from the University of Navarra in Pamplona, Spain in 1992 and a Ph.D. degree from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital ¨12 de Octubre¨ in Madrid and at the University of Texas Health Science Center in San Antonio. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio, TX. Prior to this position he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to be Director of the Gastrointestinal Oncology Programm at the Kimmel Comprehensive Cancer Center at Johns Hopkins and Associate Professor of Oncology. In 2009 he became Director of the Clinical Research Program at the Speanish National Cancer Center and Vicedirector of Translational Research in 2011. In 2015 he became the Chief of the Division of Hematology and Oncology anf Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. He was also the Theodore W. and Evenly G. Berenson Professor of Medicine at Harvard Medical School. His main focus of research has been new drug development in pancreatic cancer. His group popularized the used of Avatar mouse models for cancer research and recently contributed to the development and approval of nab-paclitaxel for pancreatic cancer treatmemt. His current work focuses on strategies for personalize medicine and inmmunotherapy in pancreatic cancer.
Dra Marcela Crosara Graduada em medicina pela Escola Paulista de Medicina- UNIFESP Fez Residencia em Oncologia no Instituto do Câncer do Estado de São Paulo- USP Trabalhou como medica assistente no Grupo de tumores gastrointestinais do Instituto do Câncer do Estado de São Paulo- USP Trabalhou como Medica titular do Centro de Oncologia do Hospital Sírio Libanês- Unidade Brasilia, com atuação em tumores do trato gastrointestinal. Atual Coordenadora do Centro de Oncologia do Hospital DF STAR/ Rede DOr Brasilia- DF
Marcelo Reis é médico e doutor em Química Biológica pela Universidade Federal do Rio de Janeiro. Especialista em genética molecular e genômica do câncer com treinamento no Ludwig Center for Cancer Genetics and Therapeutics da Universidade Johns Hopkins. Atualmente é pesquisador no Instituto D‘Or de Pesquisa e Ensino e seus esforços estão voltados para investigação dos mecanismos moleculares da formação de tumores, visando a descoberta e desenvolvimento de novas estratégias terapêuticas e marcadores moleculares para o diagóstico, prognóstico ou detecção precoce do câncer.
Médica Oncologista do Instituto do Câncer do Estado de São Paulo e da Rede D‘Or, Fellowship no Memorial Sloan Kettering Cancer Center - NY em Tumores Gastro intestinais Doutoranda em Oncologia pela FMUSP
Oncologia clínica / Tumores Geniturinários - Grupo Oncoclinicas RJ Especialização em Uro-Oncologia e Desenvolvimento de Drogas no The Royal Marsden NHS Foundation Trust / Institute of Cancer Research - London (2015-2017) Residência Medica em Oncologia Clínica no INCA (2010-2013) Membro da Diretoria SBOC-RJ 2020-2021 Membro LACOG - GU Membro Sociedade Brasileira de Oncologia Clínica (SBOC) Membro Sociedade Americana de Oncologia Clínica (ASCO) Membro Sociedade Europeia de Oncologia Clínica (ESMO)
Possui graduação em Biomedicina pela Universidade Federal do Estado do Rio de Janeiro (1983), mestrado em Biofísica - Weizmann Institutte Of Science (1986) e doutorado em Ciências Biológicas (Fisiologia) pela Universidade Federal do Rio de Janeiro (1993) e Harvard School of Public Health. Professor adjunto da Universidade Federal do Rio de Janeiro, na área de Biologia Molecular, Genética humana e de doenças infecciosas desde 1994. Atualmente é diretor de Pesquisa e Desenvolvimento , do Laboratório OC Precision Medicine , Grupo Oncoclínicas
Max S. Mano MD, PhD, MAS in Medical Leadership Medical Oncologist, Breast Cancer Group Leader, Grupo Oncoclínicas Faculty - ESMO Breast Cancer Group Faculty - SBOC Breast Cancer Group Faculty - Academy of Leadership Sciences Switzerland (ALSS)
Médica Oncologista da Oncologia D´Or. Integrante do Grupo de Oncologia Torácica e Câncer de Cabeça e Pescoço e do Núcleo de Pesquisa do Instituto do Câncer do Estado de São Paulo. Possui graduação em Medicina pela Faculdade de Medicina da Universidade de São Paulo (FMUSP). Concluiu residência médica de Clínica Médica pela FMUSP e em Oncologia Clínica no Instituto do Câncer do Estado de São Paulo/HC-FMUSP. É doutoranda do programa de Oncologia da FMUSP e realizou postdoctoral fellow no Thoracic/Head and neck Medical Oncology, The University of Texas, MD Anderson Cancer Center. Membro da ASCO, SBOC, GBOT
Dr. Monika Safford is John J. Kuiper Professor of Medicine and Chief of the Division of General Internal Medicine at Weill Cornell Medical College. She is a clinician-investigator with clinical expertise in preventive healthcare, treatment of acute and chronic illness and the coordination of care for those with complex diseases. Dr. Safford previously served at University of Alabama at Birmingham (UAB) School of Medicine as the Inaugural Endowed Professor of Diabetes Prevention and Outcomes Research, Assistant Dean for Continuing Medical Education, Associate Director of the Center for Outcomes and Effectiveness Research and Education, and Co-Director of UAB’s T32 Health Services and Comparative Effectiveness Research Training Program. She is an active principal investigator with ongoing support from the National Institutes of Health, Patient Centered Outcomes Research Institute, and industrial sources. Throughout her career as an educator, she has trained and mentored numerous medical students, graduate students, residents, fellows, and junior faculty members. She has chaired national meetings for the Society of General Internal Medicine and the American Diabetes Association for which she serves on a steering committee for an ISTEP medical education initiative and was Co-Chair of the ISTEP Writing Committee. Dr. Safford’s honors include the American Association of Medical Colleges Learning Health System Research Pioneer Award (2013-14), a Gold Honor Society Humanism Program faculty mentor appointment (2012) and multiple awards for Research Excellence from UAB Department of Medicine, including the UAB Department of Medicine Max Cooper Award for Excellence in Research.
Médico hematologista e patologista clínico, responsável pelo diagnóstico molecular em oncologia e hematologia da medicina diagnóstica Albert Einstein, pesquisador do IEP Albert Einstein e coordenador do curso de bases da genômica do câncer e oncologia de precisão do Hospital Albert Einstein.
Médico formado pela Universidade de Brasília (1991); doutorado e livre docência em Oncologia pela Faculdade de Medicina da Universidade de São Paulo, onde é professor titular; Fellowship em Hematologia e Oncologia no MD Anderson Cancer Center. Atualmente é diretor-geral do Instituto do Câncer de São Paulo “Octávio Frias de Oliveira” e membro dos Conselhos Diretores da ASCO e do Hospital das Clínicas.
Dr Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr Brentjens is an member on the faculty at MSKCC and an attending physician on the leukemia service. As a medical oncology fellow during his training at MSKCC, Dr Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19 antigen through the retroviral gene transfer of artificial T cell receptors termed chimeric antigen receptors (CARs). Following completion of his medical oncology training, Dr Brentjens became the principle investigator of his own laboratory. As a PI, Dr Brentjens successfully translated these studies to the clinical setting treating patients with relapsed CD19+ tumors including chronic lymphocytic leukemia (CLL) and B cell acute lymphoblastic leukemia (B-ALL). Ongoing pre-clinical research in the laboratory is focused on the further development of CAR modified T cells designed to overcome the hostile immunosuppressive tumor microenvironment through the generation of “armored CAR T cells” currently being translated to the clinical setting as second generation CAR modified T cell clinical trials. Additionally, work in the Brentjens’ lab has expanded this CAR technology to target additional tumor antigens expressed on other malignancies including solid tumors.
Oncologista Clínico Líder de Práticas Assistenciais em Tumores Cutâneos Grupo Oncoclínicas Pesquisador na Unidade de Pesquisa Clínica em Oncologia do Hospital de Clínicas de Porto Alegre
Romualdo Barroso-Sousa, MD, PhD Associate Physician, Translational Research Coordinator Oncology Center, Hospital Sírio-Libanês Brasília, Brazil
Faculdade de Medicina da Universidade de SP, 1973; especialização em Clínica Médica, Hematologia e Oncologia Clínica nos Estados Unidos 1974-1980; doutorado pela Universidade de São Paulo, 2003; professor assistente de Oncologia, UNIFESP 2008-2013; oncologista clínico do Hospital Israelita Albert Einstein e do Centro Paulista de Oncologia; membro da SBOC, ASCO e ESMO.
Founding Core Member, Chief Scientific Officer, and Director of the Cancer Program at the Broad Institute of MIT and Harvard Director of the Gerstner Center for Cancer Diagnostics at the Broad Institute Professor of Pediatrics at Harvard Medical School Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute
Oncologista clínico - Oncoclinica Porto Alegre e PUCRS Doutor em Ciencias Médicas pela UFRGS Diretor Cientifico do Centro de Pesquisa da Serra Gaucha (CEPESG) Ex- visiting research fellow - Washington University at St Louis
Médico pela Faculdade de Medicina da Universidade de São Paulo (FMUSP), Diretor Médico de Oncologia Clínica e Hematologia do Hospital BP, a Beneficência Portuguesa de São Paulo e Professor Adjunto Associado do MD Anderson Cancer Center, EUA.
Graduação em Medicina pela Universidade Federal de Minas Gerais. Doutora em Oncologia pelo INCA (2015). Atualmente é chefe da Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico do INCA, Oncologista do Grupo Oncoclínicas
Fundador e Presidente do Conselho de Administração do Grupo Oncoclínicas; Diretor Técnico do Grupo Oncoclínicas, Membro do Comitê de Clinical Guidelines da ASCO.
Fernando Nunes Galvão de Oliveira Medical Oncologist - CLION/ CAM Group LACOG GU board of directors ASCO/ ESMO/ SBOC member
Professor Associado - Departamento de Radiologia e Oncologia Faculdade de Medicina, Universidade de São Paulo, Instituto do Câncer do Estado de são Paulo (ICESP) - São Paulo, Brasil
Coordenador do Grupo de Sarcoma, Melanoma e Tus do SNC - ICESP Médico Titular - Centro de Oncologia do Hospital Sírio Libanes
Diretor Médico da Oncoclínicas Precision Medicine e Big Data, São Paulo. E como coordenador científico do grupo de pesquisa Oncology Data Science no Vall d‘Hebron Institute of Oncology, Barcelona.
Médico Oncologista especialista em tumores cutâneos e sarcomas do Hospital Sírio Libanês e Instituto do Câncer do Estado de São Paulo
Dean of Graduate Studies - Barretos Cancer Hospital. Executive and Scientific Director - Teaching and Research Institute, Barretos Cancer Hospital. Invited Assistant Professor - School of Medicine, University of Minho, Portugal.
Oncologista Clínica titular da Oncologia D‘Or Oncologista Clínica assistente do ICESP Ex-Research fellow of Memorial Sloan Kettering Cancer Center at the Sarcoma Center 2008



Diamond Sponsors

Gold Sponsors

Silver Sponsors